Restricting Tumor Lactic Acid Metabolism Using Dichloroacetate Improves T Cell Functions
Overview
Authors
Affiliations
Background: Lactic acid produced by tumors has been shown to overcome immune surveillance, by suppressing the activation and function of T cells in the tumor microenvironment. The strategies employed to impair tumor cell glycolysis could improve immunosurveillance and tumor growth regulation. Dichloroacetate (DCA) limits the tumor-derived lactic acid by altering the cancer cell metabolism. In this study, the effects of lactic acid on the activation and function of T cells, were analyzed by assessing T cell proliferation, cytokine production and the cellular redox state of T cells. We examined the redox system in T cells by analyzing the intracellular level of reactive oxygen species (ROS), superoxide and glutathione and gene expression of some proteins that have a role in the redox system. Then we co-cultured DCA-treated tumor cells with T cells to examine the effect of reduced tumor-derived lactic acid on proliferative response, cytokine secretion and viability of T cells.
Result: We found that lactic acid could dampen T cell function through suppression of T cell proliferation and cytokine production as well as restrain the redox system of T cells by decreasing the production of oxidant and antioxidant molecules. DCA decreased the concentration of tumor lactic acid by manipulating glucose metabolism in tumor cells. This led to increases in T cell proliferation and cytokine production and also rescued the T cells from apoptosis.
Conclusion: Taken together, our results suggest accumulation of lactic acid in the tumor microenvironment restricts T cell responses and could prevent the success of T cell therapy. DCA supports anti-tumor responses of T cells by metabolic reprogramming of tumor cells.
Targeting metabolic dysfunction of CD8 T cells and natural killer cells in cancer.
Viel S, Vivier E, Walzer T, Marcais A Nat Rev Drug Discov. 2024; 24(3):190-208.
PMID: 39668206 DOI: 10.1038/s41573-024-01098-w.
Lactate: a rising star in tumors and inflammation.
Liu H, Pan M, Liu M, Zeng L, Li Y, Huang Z Front Immunol. 2024; 15:1496390.
PMID: 39660139 PMC: 11628389. DOI: 10.3389/fimmu.2024.1496390.
Zheng Y, Xu R, Chen X, Lu Y, Zheng J, Lin Y Cell Death Dis. 2024; 15(10):775.
PMID: 39461979 PMC: 11513100. DOI: 10.1038/s41419-024-07122-6.
Lactate's impact on immune cells in sepsis: unraveling the complex interplay.
Zhang T, Chen L, Kueth G, Shao E, Wang X, Ha T Front Immunol. 2024; 15:1483400.
PMID: 39372401 PMC: 11449721. DOI: 10.3389/fimmu.2024.1483400.
Understanding lactate in the development of Hepatitis B virus-related hepatocellular carcinoma.
Sheikhrobat S, Mahmoudvand S, Kazemipour-Khabbazi S, Ramezannia Z, Baghi H, Shokri S Infect Agent Cancer. 2024; 19(1):31.
PMID: 39010155 PMC: 11247867. DOI: 10.1186/s13027-024-00593-4.